<!DOCTYPE html>
<!--
==============================================================================
           "GitHub HTML5 Pandoc Template" v2.1 — by Tristano Ajmone           
==============================================================================
Copyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:

- https://github.com/tajmone/pandoc-goodies

The CSS in this template reuses source code taken from the following projects:

- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):
  https://github.com/sindresorhus/github-markdown-css

- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):
  http://primercss.io/

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The MIT License 

Copyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)
Copyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)
Copyright (c) 2017 GitHub Inc.

"GitHub Pandoc HTML5 Template" is Copyright (c) Tristano Ajmone, 2017, released
under the MIT License (MIT); it contains readaptations of substantial portions
of the following third party softwares:

(1) "GitHub Markdown CSS", Copyright (c) Sindre Sorhus, MIT License (MIT).
(2) "Primer CSS", Copyright (c) 2016 GitHub Inc., MIT License (MIT).

Permission is hereby granted, free of charge, to any person obtaining a copy
of this software and associated documentation files (the "Software"), to deal
in the Software without restriction, including without limitation the rights
to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
copies of the Software, and to permit persons to whom the Software is
furnished to do so, subject to the following conditions:

The above copyright notice and this permission notice shall be included in all
copies or substantial portions of the Software.

THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
SOFTWARE.
==============================================================================-->
<html>
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>Hepatitis B and Fibroscan MeG-CLS-091</title>
  <style type="text/css">
@charset "UTF-8";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,"Segoe UI",Helvetica,Arial,sans-serif,"Apple Color Emoji","Segoe UI Emoji","Segoe UI Symbol";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:""}.markdown-body hr::after{display:table;clear:both;content:""}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:" "}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:""}.markdown-body::after{display:table;clear:both;content:""}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}
  </style>
  <style type="text/css">code{white-space: pre;}</style>
  <!--[if lt IE 9]>
    <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js"></script>
  <![endif]-->
</head>
<body>
<article class="markdown-body">
<h1 id="hepatitis-b">Hepatitis B</h1>
<h2 id="executive-summary">Executive summary</h2>
<h2 id="introduction">Introduction</h2>
<p>Hepatitis B virus (HBV) infection is a worldwide healthcare problem, especially in developing areas. In The Gambia, approximately 1 in every 10 adults is chronically infected with HBV. This virus can be passed in blood, from mother to child at birth, in early life from child to child with close contact, or through unprotected sex with an infected partner. For the last 25 years, all children born in The Gambia are offered vaccination against HBV. However, adults over 30 years of age were born before the vaccine was introduced and may carry the virus.</p>
<p>People with HBV may have no symptoms. However, in some people, the virus may silently damage the liver and eventually cause liver cancer and liver failure. Hence, the need for follow up of all hepatitis B patients with or without symptoms.</p>
<p>Because not everyone who is infected with HBV will develop symptoms and disease, current international guidelines recommend treatment for those HBV infected patients with or at risk of advanced liver disease or liver cancer.</p>
<h2 id="target-users">Target users</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Doctors</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Nurses</p>
</div></li>
</ul>
<h2 id="target-area-of-use">Target area of use </h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>CSD clinic</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Liver clinic</p>
</div></li>
</ul>
<h2 id="key-areas-of-focus-new-additions-changes">Key areas of focus / New additions / Changes </h2>
<p>This document outlines the initial assessment and annual review of HBV infected patients who are not on treatment, as well as the referral protocol for HBV patients between CSD and MATCH B/ Liver clinic. Also outlined is Fibroscan interpretation in chronic liver disease.</p>
<h2 id="presenting-symptoms-and-signs">Presenting symptoms and signs</h2>
<h3 id="the-pathogenesis-and-clinical-manifestations-of-hepatitis-b-are-due-to-the-interaction-of-the-virus-and-the-host-immune-system-which-leads-to-liver-injury-and-potentially-cirrhosis-and-hepatocellular-carcinoma.-patients-can-have-either-an-acute-symptomatic-disease-or-an-asymptomatic-disease.">The pathogenesis and clinical manifestations of hepatitis B are due to the interaction of the virus and the host immune system, which leads to liver injury and, potentially, cirrhosis and hepatocellular carcinoma. Patients can have either an acute symptomatic disease or an asymptomatic disease.</h3>
<p>Majority of the HBV patients who present to the MATCH B/Liver clinic and the MRCG CSD will be in the immune tolerant phase of the infection and/or will have an inactive chronic infection without any evidence of active disease. These are asymptomatic carriers. A few patients will present with chronic active hepatitis and may have symptoms ranging from those of acute hepatitis to end-stage liver disease.</p>
<p>Icteric hepatitis is associated with a prodromal period during which a serum sickness-like syndrome can occur. The symptomatology is more constitutional and includes the following:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Anorexia</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Nausea</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Vomiting</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Low-grade fever</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Myalgia</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Fatigability</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Right upper quadrant and epigastric pain (intermittent, mild to moderate)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Ascites</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Gastrointestinal bleeding</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Coagulopathy</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Mental confusion</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Coma</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Hepatic encephalopathy</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Disturbances in sleep pattern</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Somnolence</p>
</div></li>
</ul>
<h2 id="examination-findings">Examination findings</h2>
<p>The physical examination findings in hepatitis B disease vary from minimal to impressive (in patients with hepatic decompensation), according to the stage of disease.</p>
<p>Patients with acute hepatitis usually do not have any clinical findings, but the physical examination can reveal the following;</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Low-grade fever</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Jaundice</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Hepatomegaly</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Splenomegaly</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Palmar erythema</p>
</div></li>
</ul>
<p>The physical examination of patients with chronic hepatitis B virus infection can reveal stigmata of chronic liver disease such as the following:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Hepatomegaly</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Splenomegaly</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Muscle wasting</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Palmar erythema</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Vasculitis</p>
</div></li>
</ul>
<p>Patients with (decompensated) cirrhosis may have the following findings:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Ascites</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Jaundice</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>History of variceal bleeding</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Peripheral oedema</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Gynaecomastia</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Abdominal collateral veins</p>
</div></li>
</ul>
<h2 id="management">Management </h2>
<h3 id="acute-hepatitis-b-virus-infection">Acute Hepatitis B virus infection</h3>
<p>The incidence of acute HBV infection has been decreasing for a number of years due to widespread vaccination and routine blood testing. Acute HBV infection is characterised by the onset of symptoms 1–4 months after exposure. A serum sickness-like syndrome may occur, followed by an illness characterised by anorexia, nausea, jaundice and right upper quadrant pain. Symptoms usually disappear after 1–3 months, but some patients have prolonged fatigue even after liver function tests have normalised.</p>
<p>Elevated ALT/AST with values up to 1000–2000 IU/L are characteristic of acute HBV. Prothrombin time is the best guide to prognosis. In the early phase of infection, HBsAg, anti-HBc IgM and HBeAg are all positive.</p>
<p>The management of acute HBV is symptomatic care:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Bed rest and nutritional support are central.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Anti-nausea medications may be of benefit, and</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>limited doses of paracetamol (&lt; 2 g a day) or codeine may be cautiously administered for abdominal pain or fevers.</p>
</div></li>
</ul>
<p>Since most patients recover, antiviral therapy is not generally recommended. Patients should be monitored regularly with laboratory tests during the acute phase of their illness, and referred for specialist review if they have a prolonged prothrombin time, elevated serum bilirubin concentration, signs of encephalopathy, or if the illness is uncharacteristically lengthy.</p>
<p>Repeat HBV serological assessment (HBsAg, HBeAg, and anti-HBc) following recovery from the icteric illness to identify the small proportion of patients who develop CHB.</p>
<h3 id="chronic-hepatitis-b-virus-infection">Chronic Hepatitis B virus infection</h3>
<p>The physical examination in chronic HBV patients should include an assessment for spider angioma, gynecomastia, and splenomegaly, which are indicative of more advanced liver disease.</p>
<p>An assessment of family history of cirrhosis and HCC, alcohol and smoking habits, and current medication and herbal product use should be undertaken. Although prothrombin time and bilirubin are normal in most outpatients with chronic HBV, serial assessment of serum aminotransferase (i.e., aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) levels can help determine the current status of infection.</p>
<p>In addition, a complete blood count can help detect thrombocytopenia, which is an early marker of portal hypertension. Chronic HBV patients should be screened for concomitant human immunodeficiency virus coinfection.</p>
<p>Finally, a baseline serum alpha‐fetoprotein level, transient elastography (TE) or FibroScan and liver ultrasound is recommended to screen for early stage HCC, cirrhosis, and other causes of liver disease.</p>
<h3 id="initial-assessment-of-chronic-hbv-patients-not-on-treatment">Initial assessment of chronic HBV patients not on treatment</h3>
<p>History and physical examination</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Education to reduce transmission</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Test/vaccinate household and sexual contacts</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Minimize alcohol and smoking</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Family history of HCC/cirrhosis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Assess body mass index</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Examine for signs of liver disease (spider nevi, gynecomastia, ascites, collateral veins (abdomen), etc.</p>
</div></li>
</ul>
<p>Laboratory tests</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Serum AST/ALT, albumin, bilirubin, INR, complete blood count, platelet count</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Renal function (serum creatinine)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Quantitative HBV DNA viral load level</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Exclude HIV coinfection</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Serum AFP and liver ultrasound</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Transient Elastography (TE) or FibroScan</p>
</div></li>
</ul>
<h3 id="annual-followup-evaluation-for-chronic-hbv-patients-not-on-treatment">Annual follow‐up evaluation for chronic HBV patients not on treatment</h3>
<p>This should be done every 6-12 months in patients who are stable and do not require antiviral therapy. Reassessment includes:</p>
<p>History and physical examination for any liver disease or progression.</p>
<p>Laboratory tests/ Imaging</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>LFT (ALT, AST and GGT)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Serum creatinine</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Complete blood count</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Abdominal Ultrasound scan</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Transient Elastography (TE) or FibroScan</p>
</div></li>
</ul>
<h2 id="transient-elastography-te-or-fibroscan">Transient Elastography (TE) or FibroScan</h2>
<p>Transient elastography (TE) or FibroScan is a painless, non-invasive technique that estimates the degree of liver scarring. Results are measured in kilopascals (kPa) which correlate with fibrosis score as determined by biopsy. Cut-off values are given that can accurately place the patient in different stages of fibrosis. A meta-analysis of the use of TE in chronic HBV found that it performed well in detecting cirrhosis (sensitivity 85% and specificity 82%).</p>
<h3 id="indications">Indications</h3>
<div data-custom-style="Normal (Web)">
<p>FibroScan® is very useful in the assessment of patients with chronic liver disease, including chronic hepatitis C, chronic hepatitis B, chronic alcohol abuse, and non-alcoholic fatty liver disease. The concept is that as more fibrosis and scarring occur, the higher the liver stiffness reading will be. This reading may be used to:</p>
</div>
<ul>
<li><div data-custom-style="List Paragraph">
<p>estimate the existing degree of liver damage</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>monitor disease progression or regression via serial measurements</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>guide prognosis and further management, including treatment.</p>
</div></li>
</ul>
<table>
<thead>
<tr class="header">
<th><strong>FIBROSCAN VALUE(KPa)</strong></th>
<th><strong>2-7.4</strong></th>
<th><strong>7.5-8.2</strong></th>
<th><strong>8.3-9.4</strong></th>
<th><strong>≥9.5</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>METAVIR</strong></td>
<td>F0/F1</td>
<td>F2</td>
<td>F3</td>
<td>F4</td>
</tr>
<tr class="even">
<td><strong>INTERPRETATION</strong></td>
<td>No or mild fibrosis</td>
<td>Fibrosis</td>
<td>Significant fibrosis</td>
<td>Cirrhosis</td>
</tr>
</tbody>
</table>
<p>Possible reasons for an over-estimation of FibroScan:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Liver inflammation (eg. active hepatitis)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Cholestasis (eg. biliary obstruction)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Mass lesions within the liver (eg. tumour)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Liver congestion (eg. heart failure)</p>
</div></li>
</ul>
<p>Failure or unreliable readings are seen more frequently in patients with the following characteristics:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Obesity (BMI &gt;30–35 kg/m<sup>2</sup>)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Older age</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Presence of ascites</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Features of the metabolic syndrome (type 2 diabetes, hypertension, increased waist circumference)</p>
</div></li>
</ul>
<p><strong><br />
</strong></p>
<p><strong>Algorithm for referral of hepatitis b patients to match b/ liver clinic</strong></p>
<p><strong><br />
</strong></p>
<h2 id="general-recommendations-for-hbv-patients">General recommendations for HBV patients</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Minimize alcohol consumption</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Stop smoking</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Stop eating mouldy groundnuts</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Avoid toxins and herbal medications</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Balanced diet and exercise to reduce insulin resistance/hepatic steatosis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Acetaminophen analgesics &lt; 4 g/day preferred over NSAIDs/aspirin</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Use of steroids/immunosuppressants/chemotherapy requires prophylactic oral antiviral</p>
</div></li>
</ul>
<h2 id="references">References</h2>
<p>Terrault N, Bzowej N, Chang K, Hwang JP, Jonas MM, Murad MH; American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016;63:261-83.</p>
<p>European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370-98.</p>
<p>Lemoine M, Shimakawa Y, Nayagam S, et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. Gut 2015.</p>
<table>
<thead>
<tr class="header">
<th>Written by:</th>
<th>Name: Sulayman Bah</th>
<th>Date: 24 March 2020</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Reviewed by:</td>
<td>Name: Gibril Ndow</td>
<td>Date: 16 April 2020</td>
</tr>
<tr class="even">
<td>Version:</td>
<td>Change history:</td>
<td>Review due date:</td>
</tr>
<tr class="odd">
<td>1.0</td>
<td>New document</td>
<td>16 April 2022</td>
</tr>
<tr class="even">
<td>Review Comments (if applicable)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</article>
</body>
</html>
